Sangamo Therapeutics (SGMOQ) Current Deferred Revenue (2010 - 2025)

Sangamo Therapeutics' Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $899000.0 for Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 88.1% year-over-year to $899000.0 in Q4 2025; TTM through Dec 2025 was $899000.0, a 88.1% decrease from a year earlier, with the FY2025 full-year figure at $899000.0, down 88.1% from the prior year.
• Current Deferred Revenue fell to $899000.0 in Q4 2025 per SGMOQ's latest filing, from $7.6 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $94.4 million in Q1 2021 and bottomed at $774000.0 in Q3 2024.
• The 5-year median for Current Deferred Revenue is $9.6 million (2023), against an average of $41.0 million.
• Across the five-year window, Current Deferred Revenue tumbled 97.93% in 2023 and soared 876.23% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $85.7 million in 2021, then slumped by 39.59% to $51.8 million in 2022, then slumped by 97.13% to $1.5 million in 2023, then surged by 408.82% to $7.6 million in 2024, then tumbled by 88.1% to $899000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Current Deferred Revenue figures stand at $899000.0 (Q4 2025), $7.6 million (Q3 2025), and $7.6 million (Q2 2025).